Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer

Volumn 94, Issue 9, 2006, Pages 1233-1236

  Pacilio, C ^a   Morabito, A ^a   Nuzzo, F ^a   Gravina, A ^a   Labonia, V ^a   Landi, G ^a   Rossi, E ^a   De Maio, E ^a   Di Maio, M ^a   D'Aiuto, G ^a   Botti, G ^a   Normanno, N ^b   Chiodini, P ^c   Gallo, C ^c   Perrone, F ^a   De Matteis, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Adjuvant anthracyclines; Docetaxel; Epirubicin; Metastatic breast cancer; Randomised trials

Indexed keywords

ANTHRACENE DERIVATIVE; DOCETAXEL; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE;

ADULT; ALLERGY; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAIR LOSS; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; VOMITING; WEIGHT REDUCTION;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TAXOIDS;

EID: 33646510888     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603096     Document Type: Article

References (15)

1. Buzdar AU, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR (1981) Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47: 2798-2802
2. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J, 303 Study Group (1999) Prospective randomized trial of docetaxel vs doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354
3. Chauvin F, Magnet M, Lasset C, Catimel G, Mayer M, Chevarier P, Jacquin JP, Peaud P, Clavel M (1990) Prognostic factors in the response of a first line chemotherapy in advanced breast cancer. Bull Cancer 77: 941-947
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
5. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31150 women. J Clin Oncol 16: 3439-3460
6. Gennari A, Bruzzi P, Orlandini C, Salvadori B, Donati S, Landucci E, Guarneri V, Rondini M, Ricci S, Conte P (2004) Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer 90: 962-967
7. Johns D, Andersen JS (1999) Use of predictive probabilities in phase II and phase III clinical trials. J Biopharm Stat 9: 67-79
8. Kardinal CG, Perry MC, Korzun AH, Rice MA, Ginsberg S, Wood WC (1988) Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. Cancer 61: 415-419
9. Mavroudis D, Alexopoulos A, Ziras N, Malamos N, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Tsavaris N, Potamianou A, Rigatos G, Georgoulias V (2000) Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 11: 1249-1254
10. Nabholtz J-M, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M, 304 Study Group (1999) Prospective randomized trial of docetaxel vs mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413-1424
11. Pagani O, Sessa C, Nole F, Crivellari D, Lombardi D, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D'Incalci M, Goldhirsch A (2000) Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 11: 985-991
12. Pierga JY, Asselain B, Jouve M, Dieras V, Carton M, Laurence V, Girre V, Beuzeboc P, Palangie T, Dorval T, Pouillart P (2001) Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer 91: 1079-1089
13. Valagussa P, Tancini G, Bonadonna G (1986) Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58: 1411-1417
14. Valero V, Hortobagyi GN (2003) Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 21: 959-962
15. Venturini M, Bruzzi P, Del Mastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR (1996) Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 14: 764-773